Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1842251
PUBLISHER: Grand View Research | PRODUCT CODE: 1842251
Middle East Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Age Group, By Route Of Administration, By Distribution Channel, By Country, And Segment Forecasts, 2025 - 2033
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Middle East Pharmaceutical Market Summary
The Middle East pharmaceutical market size was estimated at USD 54.28 billion in 2024 and is projected to reach USD 78.30 billion by 2033, growing at a CAGR of 4.04% fom 2025 to 2033. The market is fueled by the growing prevalence of chronic diseases, an aging population, and increased healthcare expenditures.
The pharmaceutical market in the Middle East is undergoing notable transformation due to strategic reforms and a growing focus on local production, technological integration, and evolving regulatory standards. In January 2025, the UAE's Emirates Drug Establishment (EDE) introduced new regulations under Federal Decree-Law No. 38/2024, which provides an accelerated approval process for innovative drugs, including biosimilars. This policy aims to address the rising demand for cost-effective treatments for chronic diseases such as diabetes, cardiovascular diseases, and cancer. The fast-track approval process for biosimilars is expected to significantly lower drug prices and improve accessibility across the region. This move has been regarded as a critical development in enabling broader access to biologics in the Middle East, where healthcare expenditure has been rising sharply.
Another major factor influencing the region's pharmaceutical market is the increasing incidence of chronic diseases. The EMRO region has the highest prevalence of diabetes globally, ranging from 7% in Somalia to 18% in Egypt. In addition, countries such as Bahrain, Kuwait, Saudi Arabia, and the United Arab Emirates report high rates of overweight and obesity, exceeding 70%, particularly among women. Physical inactivity rates are also elevated, with about 50% of women and over a third of men not engaging in sufficient physical activity. To address this, A recent partnership in July 2025, between Jamjoom Pharma and Althera Laboratories aims to bring a dual-action cholesterol-lowering therapy to Saudi Arabia, with a targeted launch in 2027. This initiative reflects ongoing efforts to enhance access to modern lipid-lowering treatments.
The Middle East is also witnessing a shift towards self-sufficiency in pharmaceutical production, a trend that is being actively supported by regional governments. In January 2025, the UAE's pharmaceutical sector experienced significant growth, with over 35 pharmaceutical factories now operating nationwide. The government aims to expand local drug production capacity by 40% in the next year, enhancing access to medicines and fostering a more self-reliant healthcare system. This initiative has led to significant collaborations with global pharmaceutical companies to build local production capacities, particularly in biologics and vaccines. In March 2025, Julphar announced a strategic licensing partnership with Dong-A ST, a South Korean biotech firm, to launch an innovative biotechnology product in the MENA region. This partnership aims to introduce a new biosimilar monoclonal antibody for rheumatoid arthritis, which is expected to enhance access to affordable treatment options in the region. This marks a significant step in reducing the region's dependence on imported biologics and increasing its production capabilities for high-value therapeutic areas.
Technological advancements are also playing a critical role in shaping the pharmaceutical landscape in the Middle East. In January 2025, the DHA highlighted its adoption of Robotic Process Automation (RPA) technologies to enhance investor services and healthcare licensing processes. This initiative aligns with global trends toward digitalization and service quality improvement. The RPA program is one of the DHA's most ambitious initiatives, developed to address the increasing demand from healthcare facilities and professionals seeking licensing to operate in Dubai. The program employs software robots that replicate human actions when interacting with digital systems, representing a transformative upgrade to the DHA's "Sheryan" platform.. This platform facilitating faster drug approvals and more efficient distribution networks. The DHA's initiative is part of a broader effort to integrate digital health technologies across the UAE, enabling the country to become a leader in health-tech innovation and improving access to pharmaceutical products.
Furthermore, the Middle East has become a regional leader in combating counterfeit medicines, a growing problem across emerging markets. As of January 2024, all pharmaceutical products sold in Kuwait are required to be marked with a GS1 DataMatrix barcode containing four key data elements: Global Trade Item Number (GTIN), batch number, expiration date, and a unique serial number. In addition, the regulatory authorities in the GCC began implementing stricter guidelines for the distribution and storage of medicines, ensuring better control over the pharmaceutical supply chain. This framework aligns with the GHC's broader objectives to harmonize healthcare regulations and improve patient safety across region.These regulatory advancements, combined with growing local production capacity and technological innovation, underscore the Middle East's commitment to transforming its pharmaceutical market. The sector is expected to experience robust growth over the coming years, creating new opportunities for both local manufacturers and international stakeholders in the region.
Middle East Pharmaceutical Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East pharmaceutical market report based on molecule type, product, type, disease, route of administration, age group, distribution channel, and country.
- Molecule Type Outlook (Revenue, USD Million, 2021 - 2033)
- Biologics & Biosimilars (Large Molecules)
- Monoclonal Antibodies
- Vaccines
- Cell & Gene Therapy
- Others
- Conventional Drugs (Small Molecules)
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Branded
- Generics
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Prescription
- OTC
- Disease Outlook (Revenue, USD Million, 2021 - 2033)
- Cardiovascular diseases
- Cancer
- Diabetes
- Infectious diseases
- Neurological disorders
- Respiratory diseases
- Autoimmune diseases
- Mental health disorders
- Gastrointestinal disorders
- Women's health diseases
- Genetic and rare genetic diseases
- Dermatological conditions
- Obesity
- Renal diseases
- Liver conditions
- Hematological disorders
- Eye conditions
- Infertility conditions
- Endocrine disorders
- Allergies
- Others
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Tablets
- Capsules
- Suspensions
- Other
- Topical
- Parenteral
- Intravenous
- Intramuscular
- Inhalations
- Other
- Age Group Outlook (Revenue, USD Million, 2021 - 2033)
- Children & Adolescents
- Adults
- Geriatric
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Others
- Country Outlook (Revenue, USD Million, 2021 - 2033)
- Middle East
- UAE
- Saudi Arabia
- Kuwait
- Qatar
- Oman
- Rest of Middle East
Product Code: GVR-4-68040-728-8
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.2.5. Country scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product and Application Outlook
- 2.2.2. Route of Administration and Distribution Channel outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Middle East Pharmaceutical Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of chronic diseases such as diabetes and obesity
- 3.2.1.2. Increasing R&D activities for developing novel therapeutics
- 3.2.1.3. Formulation advancements of oral Pharmaceuticals
- 3.2.1.4. Increasing awareness about diagnosis and treatment options for diabetes
- 3.2.2. Market restraint analysis
- 3.2.2.1. Product failure
- 3.2.2.2. Patent expiry of blockbuster drugs during the forecast period
- 3.2.1. Market driver analysis
- 3.3. Middle East Pharmaceutical Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.1. Industry Analysis - Porter's
- 3.4. Pricing Analysis
- 3.5. Pipeline Analysis
- 3.6. Patent Expiry Analysis
Chapter 4. Middle East Pharmaceutical Market: Molecule Type Estimates & Trend Analysis
- 4.1. Middle East Pharmaceutical Market: Drug Segment Dashboard
- 4.2. Middle East Pharmaceutical Market: Molecule Type Movement Analysis, USD Million, 2024 & 2030
- 4.3. Biologics & Biosimilars (Large Molecules)
- 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2. Monoclonal Antibodies
- 4.3.2.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Vaccines
- 4.3.3.1. Vaccines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.4. Cell & Gene Therapy
- 4.3.4.1. Cell & Gene Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.5. Others
- 4.3.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Conventional Drugs (Small Molecules)
- 4.4.1. Conventional Drugs (Small Molecules) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Middle East Pharmaceutical Market: Type Estimates & Trend Analysis
- 5.1. Middle East Pharmaceutical Market: Type Segment Dashboard
- 5.2. Middle East Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
- 5.3. Prescription
- 5.3.1. Prescription Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. OTC
- 5.4.1. OTC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Middle East Pharmaceutical Market: Product Estimates & Trend Analysis
- 6.1. Middle East Pharmaceutical Market: Product Segment Dashboard
- 6.2. Middle East Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
- 6.3. Branded
- 6.3.1. Branded Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Generics
- 6.4.1. Generics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Middle East Pharmaceutical Market: Disease Estimates & Trend Analysis
- 7.1. Middle East Pharmaceutical Market: Disease Segment Dashboard
- 7.2. Middle East Pharmaceutical Market: By Disease Movement Analysis, USD Million, 2024 & 2030
- 7.3. Cardiovascular diseases
- 7.3.1. Cardiovascular diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Cancer
- 7.4.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Diabetes
- 7.5.1. Diabetes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Infectious diseases
- 7.6.1. Infectious diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Neurological disorders
- 7.7.1. Neurological disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Respiratory diseases
- 7.8.1. Respiratory diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9. Autoimmune diseases
- 7.9.1. Autoimmune diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.10. Mental health disorders
- 7.10.1. Mental health disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.11. Gastrointestinal disorders
- 7.11.1. Gastrointestinal disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.12. Women's Health Diseases
- 7.12.1. Women's Health Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.13. Genetic and Rare genetic diseases
- 7.13.1. Genetic and Rare genetic diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.14. Dermatological conditions
- 7.14.1. Dermatological conditions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.15. Obesity
- 7.15.1. Obesity Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.16. Renal diseases
- 7.16.1. Renal diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.17. Liver conditions
- 7.17.1. Liver conditions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.18. Hematological disorders
- 7.18.1. Hematological disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.19. Eye conditions
- 7.19.1. Eye conditions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.20. Infertility conditions
- 7.20.1. Infertility conditions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.21. Endocrine disorders
- 7.21.1. Endocrine disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.22. Allergies
- 7.22.1. Allergies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.23. Others
- 7.23.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Middle East Pharmaceutical Market: Route of Administration Estimates & Trend Analysis
- 8.1. Middle East Pharmaceutical Market: Route of Administration Segment Dashboard
- 8.2. Middle East Pharmaceutical Market: By Route of Administration Movement Analysis, USD Million, 2024 & 2030
- 8.3. Oral
- 8.3.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. Tablets
- 8.3.2.1. Tablets Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3. Capsules
- 8.3.3.1. Capsules Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.4. Suspensions
- 8.3.4.1. Suspensions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.5. Other
- 8.3.5.1. Other Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4. Topical
- 8.4.1. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Parenteral
- 8.5.1. Parenteral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. Intravenous
- 8.5.2.1. Intravenous Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Intramuscular
- 8.5.3.1. Intramuscular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Inhalations
- 8.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Other Routes of Administration
- 8.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Middle East Pharmaceutical Market: Age Group Estimates & Trend Analysis
- 9.1. Middle East Pharmaceutical Market: Age Group Segment Dashboard
- 9.2. Middle East Pharmaceutical Market: By Age Group Movement Analysis, USD Million, 2024 & 2030
- 9.3. Children & Adolescents
- 9.3.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4. Adults
- 9.4.1. Adults Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. Geriatric
- 9.5.1. Geriatric Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Middle East Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis
- 10.1. Middle East Pharmaceutical Market: Distribution Channel Segment Dashboard
- 10.2. Middle East Pharmaceutical Market: By Distribution Channel Movement Analysis, USD Million, 2024 & 2030
- 10.3. Hospital Pharmacy
- 10.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 10.4. Retail Pharmacy
- 10.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 10.5. Others
- 10.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 11. Middle East Pharmaceutical Market: Regional Estimates & Trend Analysis By Product, Application, Route of Administration, and Distribution Channel
- 11.1. Regional Dashboard
- 11.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 11.3. Middle East
- 11.3.1. Saudi Arabia
- 11.3.1.1. Key country dynamics
- 11.3.1.2. Regulatory framework/ reimbursement structure
- 11.3.1.3. Competitive scenario
- 11.3.1.4. Saudi Arabia market estimates and forecasts 2021 to 2033, (USD Million)
- 11.3.2. UAE
- 11.3.2.1. Key country dynamics
- 11.3.2.2. Regulatory framework/ reimbursement structure
- 11.3.2.3. Competitive scenario
- 11.3.2.4. UAE market estimates and forecasts 2021 to 2033, (USD Million)
- 11.3.3. Kuwait
- 11.3.3.1. Key country dynamics
- 11.3.3.2. Regulatory framework/ reimbursement structure
- 11.3.3.3. Competitive scenario
- 11.3.3.4. Kuwait market estimates and forecasts 2021 to 2033, (USD Million)
- 11.3.4. Qatar
- 11.3.4.1. Key country dynamics
- 11.3.4.2. Regulatory framework/ reimbursement structure
- 11.3.4.3. Competitive scenario
- 11.3.4.4. Qatar market estimates and forecasts 2021 to 2033, (USD Million)
- 11.3.5. Oman
- 11.3.5.1. Key country dynamics
- 11.3.5.2. Regulatory framework/ reimbursement structure
- 11.3.5.3. Competitive scenario
- 11.3.5.4. Oman market estimates and forecasts 2021 to 2033, (USD Million)
- 11.3.6. Rest of Middle East
- 11.3.6.1. Key country dynamics
- 11.3.6.2. Regulatory framework/ reimbursement structure
- 11.3.6.3. Competitive scenario
- 11.3.6.4. Rest of Middle East market estimates and forecasts 2021 to 2033, (USD Million)
- 11.3.1. Saudi Arabia
Chapter 12. Competitive Landscape
- 12.1. Company/Competition Categorization
- 12.2. Participant Overview
- 12.3. Financial Overview
- 12.4. Product Benchmarking
- 12.5. Company Market Share Analysis, 2024
- 12.6. Strategy Mapping
- 12.7. Company Profiles
- 12.7.1. F. Hoffmann-La Roche Ltd
- 12.7.1.1. Company overview
- 12.7.1.2. Financial performance
- 12.7.1.3. benchmarking
- 12.7.1.4. Strategic initiatives
- 12.7.2. Novartis AG
- 12.7.2.1. Company overview
- 12.7.2.2. Financial performance
- 12.7.2.3. benchmarking
- 12.7.2.4. Strategic initiatives
- 12.7.3. AbbVie Inc.
- 12.7.3.1. Company overview
- 12.7.3.2. Financial performance
- 12.7.3.3. benchmarking
- 12.7.3.4. Strategic initiatives
- 12.7.4. Johnson & Johnson Services, Inc.
- 12.7.4.1. Company overview
- 12.7.4.2. Financial performance
- 12.7.4.3. benchmarking
- 12.7.4.4. Strategic initiatives
- 12.7.5. Merck & Co., Inc.
- 12.7.5.1. Company overview
- 12.7.5.2. Financial performance
- 12.7.5.3. benchmarking
- 12.7.5.4. Strategic initiatives
- 12.7.6. Pfizer Inc.
- 12.7.6.1. Company overview
- 12.7.6.2. Financial performance
- 12.7.6.3. benchmarking
- 12.7.6.4. Strategic initiatives
- 12.7.7. Bristol-Myers Squibb Company
- 12.7.7.1. Company overview
- 12.7.7.2. Financial performance
- 12.7.7.3. benchmarking
- 12.7.7.4. Strategic initiatives
- 12.7.8. Sanofi
- 12.7.8.1. Company overview
- 12.7.8.2. Financial performance
- 12.7.8.3. benchmarking
- 12.7.8.4. Strategic initiatives
- 12.7.9. GlaxoSmithKline plc.
- 12.7.9.1. Company overview
- 12.7.9.2. Financial performance
- 12.7.9.3. benchmarking
- 12.7.9.4. Strategic initiatives
- 12.7.10. AstraZeneca
- 12.7.10.1. Company overview
- 12.7.10.2. Financial performance
- 12.7.10.3. benchmarking
- 12.7.10.4. Strategic initiatives
- 12.7.11. Takeda Pharmaceutical Co., Ltd.
- 12.7.11.1. Company overview
- 12.7.11.2. Financial performance
- 12.7.11.3. benchmarking
- 12.7.11.4. Strategic initiatives
- 12.7.1. F. Hoffmann-La Roche Ltd
Product Code: GVR-4-68040-728-8
List of Tables
- Table 1 Index of Tables
- Table 2 List of key distributors and channel partners
- Table 3 List of key emerging companies/technology disruptors/innovators
- Table 4 Middle East Pharmaceutical Market, By Molecule Type, 2021 - 2033 (USD Million)
- Table 5 Middle East Pharmaceutical Market, By Product, 2021 - 2033 (USD Million)
- Table 6 Middle East Pharmaceutical Market, By Type, 2021 - 2033 (USD Million)
- Table 7 Middle East Pharmaceutical Market, By Diseases, 2021 - 2033 (USD Million)
- Table 8 Middle East Pharmaceutical Market, By Route of Administration, 2021 - 2033 (USD Million)
- Table 9 Middle East Pharmaceutical Market, By Age Group, 2021 - 2033 (USD Million)
- Table 10 Middle East Pharmaceutical Market, By Distribution Channel, 2021 - 2033 (USD Million)
- Table 11 Saudi Arabia Pharmaceutical Market, By Molecule Type, 2021 - 2033 (USD Million)
- Table 12 Saudi Arabia Pharmaceutical Market, By Product, 2021 - 2033 (USD Million)
- Table 13 Saudi Arabia Pharmaceutical Market, By Type, 2021 - 2033 (USD Million)
- Table 14 Saudi Arabia Pharmaceutical Market, By Diseases, 2021 - 2033 (USD Million)
- Table 15 Saudi Arabia Pharmaceutical Market, By Route of Administration, 2021 - 2033 (USD Million)
- Table 16 Saudi Arabia Pharmaceutical Market, By Age Group, 2021 - 2033 (USD Million)
- Table 17 Saudi Arabia Pharmaceutical Market, By Distribution Channel, 2021 - 2033 (USD Million)
- Table 18 UAE Pharmaceutical Market, By Molecule Type, 2021 - 2033 (USD Million)
- Table 19 UAE Pharmaceutical Market, By Product, 2021 - 2033 (USD Million)
- Table 20 UAE Pharmaceutical Market, By Type, 2021 - 2033 (USD Million)
- Table 21 UAE Pharmaceutical Market, By Diseases, 2021 - 2033 (USD Million)
- Table 22 UAE Pharmaceutical Market, By Route of Administration, 2021 - 2033 (USD Million)
- Table 23 UAE Pharmaceutical Market, By Age Group, 2021 - 2033 (USD Million)
- Table 24 UAE Pharmaceutical Market, By Distribution Channel, 2021 - 2033 (USD Million)
- Table 25 Kuwait Pharmaceutical Market, By Molecule Type, 2021 - 2033 (USD Million)
- Table 26 Kuwait Pharmaceutical Market, By Product, 2021 - 2033 (USD Million)
- Table 27 Kuwait Pharmaceutical Market, By Type, 2021 - 2033 (USD Million)
- Table 28 Kuwait Pharmaceutical Market, By Diseases, 2021 - 2033 (USD Million)
- Table 29 Kuwait Pharmaceutical Market, By Route of Administration, 2021 - 2033 (USD Million)
- Table 30 Kuwait Pharmaceutical Market, By Age Group, 2021 - 2033 (USD Million)
- Table 31 Kuwait Pharmaceutical Market, By Distribution Channel, 2021 - 2033 (USD Million)
- Table 32 Qatar Pharmaceutical Market, By Molecule Type, 2021 - 2033 (USD Million)
- Table 33 Qatar Pharmaceutical Market, By Product, 2021 - 2033 (USD Million)
- Table 34 Qatar Pharmaceutical Market, By Type, 2021 - 2033 (USD Million)
- Table 35 Qatar Pharmaceutical Market, By Diseases, 2021 - 2033 (USD Million)
- Table 36 Qatar Pharmaceutical Market, By Route of Administration, 2021 - 2033 (USD Million)
- Table 37 Qatar Pharmaceutical Market, By Age Group, 2021 - 2033 (USD Million)
- Table 38 Qatar Pharmaceutical Market, By Distribution Channel, 2021 - 2033 (USD Million)
- Table 39 Oman Pharmaceutical Market, By Molecule Type, 2021 - 2033 (USD Million)
- Table 40 Oman Pharmaceutical Market, By Product, 2021 - 2033 (USD Million)
- Table 41 Oman Pharmaceutical Market, By Type, 2021 - 2033 (USD Million)
- Table 42 Oman Pharmaceutical Market, By Diseases, 2021 - 2033 (USD Million)
- Table 43 Oman Pharmaceutical Market, By Route of Administration, 2021 - 2033 (USD Million)
- Table 44 Oman Pharmaceutical Market, By Age Group, 2021 - 2033 (USD Million)
- Table 45 Oman Pharmaceutical Market, By Distribution Channel, 2021 - 2033 (USD Million)
- Table 46 Rest of Middle East Pharmaceutical Market, By Molecule Type, 2021 - 2033 (USD Million)
- Table 47 Rest of Middle East Pharmaceutical Market, By Product, 2021 - 2033 (USD Million)
- Table 48 Rest of Middle East Pharmaceutical Market, By Type, 2021 - 2033 (USD Million)
- Table 49 Rest of Middle East Pharmaceutical Market, By Diseases, 2021 - 2033 (USD Million)
- Table 50 Rest of Middle East Pharmaceutical Market, By Route of Administration, 2021 - 2033 (USD Million)
- Table 51 Rest of Middle East Pharmaceutical Market, By Age Group, 2021 - 2033 (USD Million)
- Table 52 Rest of Middle East Pharmaceutical Market, By Distribution Channel, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 Middle East Pharmaceutical Market segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value chain-based sizing & forecasting
- Fig. 7 QFD modelling for market share assessment
- Fig. 8 Middle East Pharmaceutical market: Molecule type outlook and key takeaways
- Fig. 9 Middle East Pharmaceutical market: Molecule type movement analysis & market share 2024 & 2030
- Fig. 10 Biologics & biosimilars (large molecules) market, 2021 - 2033 (USD Million)
- Fig. 11 Monoclonal Antibodies market, 2021 - 2033 (USD Million)
- Fig. 12 Vaccines market, 2021 - 2033 (USD Million)
- Fig. 13 Cell & Gene Therapy market, 2021 - 2033 (USD Million)
- Fig. 14 Others market, 2021 - 2033 (USD Million)
- Fig. 15 Conventional drugs (small molecules) market, 2021 - 2033 (USD Million)
- Fig. 16 Middle East Pharmaceutical market: Product outlook and key takeaways
- Fig. 17 Middle East Pharmaceutical market: Product movement analysis & market share 2024 & 2030
- Fig. 18 Branded pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 19 Generics pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 20 Middle East Pharmaceutical market: Type outlook and key takeaways
- Fig. 21 Middle East Pharmaceutical market: Type movement analysis & market share 2024 & 2030
- Fig. 22 Prescription pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 23 OTC pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 24 Middle East Pharmaceutical market: Disease outlook and key takeaways
- Fig. 25 Middle East Pharmaceutical market: Disease movement analysis & market share 2024 & 2030
- Fig. 26 Cancer market, 2021 - 2033 (USD Million)
- Fig. 27 Cardiovascular diseases market, 2021 - 2033 (USD Million)
- Fig. 28 Diabetes market, 2021 - 2033 (USD Million)
- Fig. 29 Infectious diseases market, 2021 - 2033 (USD Million)
- Fig. 30 Neurological disorders market, 2021 - 2033 (USD Million)
- Fig. 31 Respiratory diseases market, 2021 - 2033 (USD Million)
- Fig. 32 Autoimmune diseases market, 2021 - 2033 (USD Million)
- Fig. 33 Mental health disorders market, 2021 - 2033 (USD Million)
- Fig. 34 Gastrointestinal diseases market, 2021 - 2033 (USD Million)
- Fig. 35 Women's health diseases market, 2021 - 2033 (USD Million)
- Fig. 36 Genetic and rare genetic diseases market, 2021 - 2033 (USD Million)
- Fig. 37 Dermatological conditions market, 2021 - 2033 (USD Million)
- Fig. 38 Obesity market, 2021 - 2033 (USD Million)
- Fig. 39 Renal diseases market, 2021 - 2033 (USD Million)
- Fig. 40 Liver conditions market, 2021 - 2033 (USD Million)
- Fig. 41 Hemotological disorders market, 2021 - 2033 (USD Million)
- Fig. 42 Eye conditions market, 2021 - 2033 (USD Million)
- Fig. 43 Infertility conditions market, 2021 - 2033 (USD Million)
- Fig. 44 Endocrine disorders market, 2021 - 2033 (USD Million)
- Fig. 45 Allergies market, 2021 - 2033 (USD Million)
- Fig. 46 Other diseases market, 2021 - 2033 (USD Million)
- Fig. 47 Middle East Pharmaceutical market: Route of administration outlook and key takeaways
- Fig. 48 Middle East Pharmaceutical market: Route of administration movement analysis & market share 2024 & 2033
- Fig. 49 Oral pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 50 Tablets pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 51 Capsules pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 52 Suspensions pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 53 Others formulation pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 54 Topical pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 55 Parenteral pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 56 Intravenous market, 2021 - 2033 (USD Million)
- Fig. 57 Intramuscular market, 2021 - 2033 (USD Million)
- Fig. 58 Inhalations pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 59 Others pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 60 Middle East Pharmaceutical market: Age group outlook and key takeaways
- Fig. 61 Middle East Pharmaceutical market: Age group movement analysis & market share 2024 & 2033
- Fig. 62 Children & Adolescents pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 63 Adults pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 64 Geriatric pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 65 Middle East Pharmaceutical market: Distribution Channel outlook and key takeaways
- Fig. 66 Middle East Pharmaceutical market: Distribution Channel movement analysis & market share 2024 & 2033
- Fig. 67 Hospital Pharmacy pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 68 Retail Pharmacy pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 69 Others pharmaceutical market, 2021 - 2033 (USD Million)
- Fig. 70 Middle East market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
- Fig. 71 Saudi Arabia market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
- Fig. 72 UAE market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
- Fig. 73 Kuwait market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
- Fig. 74 Qatar market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
- Fig. 75 Oman market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
- Fig. 76 Rest of Middle East market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.